Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.70
ALIM's Cash to Debt is ranked lower than
69% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. ALIM: 0.70 )
Ranked among companies with meaningful Cash to Debt only.
ALIM' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 6.29 Max: N/A
Current: 0.7
Equity to Asset 0.27
ALIM's Equity to Asset is ranked lower than
90% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALIM: 0.27 )
Ranked among companies with meaningful Equity to Asset only.
ALIM' s Equity to Asset Range Over the Past 10 Years
Min: -0.25  Med: 0.29 Max: 0.46
Current: 0.27
-0.25
0.46
F-Score: 4
Z-Score: -8.46
M-Score: -1.49
WACC vs ROIC
13.19%
-158.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -151.41
ALIM's Operating margin (%) is ranked lower than
90% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. ALIM: -151.41 )
Ranked among companies with meaningful Operating margin (%) only.
ALIM' s Operating margin (%) Range Over the Past 10 Years
Min: -1837.82  Med: -391.16 Max: -173.81
Current: -151.41
-1837.82
-173.81
Net-margin (%) -131.67
ALIM's Net-margin (%) is ranked lower than
89% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. ALIM: -131.67 )
Ranked among companies with meaningful Net-margin (%) only.
ALIM' s Net-margin (%) Range Over the Past 10 Years
Min: -2469.5  Med: -426.33 Max: -136.58
Current: -131.67
-2469.5
-136.58
ROE (%) -106.32
ALIM's ROE (%) is ranked lower than
94% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. ALIM: -106.32 )
Ranked among companies with meaningful ROE (%) only.
ALIM' s ROE (%) Range Over the Past 10 Years
Min: -299.13  Med: -80.82 Max: -61.59
Current: -106.32
-299.13
-61.59
ROA (%) -40.43
ALIM's ROA (%) is ranked lower than
89% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. ALIM: -40.43 )
Ranked among companies with meaningful ROA (%) only.
ALIM' s ROA (%) Range Over the Past 10 Years
Min: -329.68  Med: -47.35 Max: -20.46
Current: -40.43
-329.68
-20.46
ROC (Joel Greenblatt) (%) -473.27
ALIM's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. ALIM: -473.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALIM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12187.14  Med: -3400.49 Max: -751.64
Current: -473.27
-12187.14
-751.64
EBITDA Growth (3Y)(%) 11.00
ALIM's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ALIM: 11.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALIM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -9.40 Max: 13.5
Current: 11
0
13.5
EPS Growth (3Y)(%) 3.10
ALIM's EPS Growth (3Y)(%) is ranked lower than
58% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ALIM: 3.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALIM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.40 Max: 19.7
Current: 3.1
0
19.7
» ALIM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

ALIM Guru Trades in Q3 2014

Columbia Wanger Sold Out
» More
Q3 2015

ALIM Guru Trades in Q3 2015

Jim Simons 127,149 sh (New)
» More
Q4 2015

ALIM Guru Trades in Q4 2015

Jim Simons 75,200 sh (-40.86%)
» More
Q1 2016

ALIM Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:PMXSF, NAS:NTEC, AMEX:AXN, OTCPK:BIOYF, NAS:TNXP, AMEX:NNVC, OTCPK:MBGRF, NAS:NVGN, NAS:ALQA, NAS:ASMB, OTCPK:NNAB, OTCPK:SUWN, NAS:PRPH, NAS:ECTE, OTCPK:NEVPF, OTCPK:INNV, NAS:IMNP, OTCPK:CHEXF, AMEX:CPHI, NAS:OASM » details
Traded in other countries:ASZ.Germany,
Alimera Sciences Inc is a pharmaceutical company. The Company, along with its subsidiaries is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Alimera Sciences Inc is a Delaware corporation incorporated on June 4, 2003. The Company, along with its subsidiaries is engaged in the research, development and commercialization of presecription ophthalmic pharmaceuticals. The Company's commercial product ILUVIEN, was developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can cause severe vision loss and blindness. ILUVIEN has received marketing authorization in the U.S., Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, and the United Kingdom and has been recommended for marketing authorization in Poland. ILUVIEN is an intravitreal implant that treats patients by delivering a consistent sub-microgram daily dose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, which is sustained through 36 months. ILUVIEN is inserted in a non-surgical procedure employing a device with a 25-gauge needle which allows for a self-sealing wound. In approved European countries, the procedure is performed in a hospital or private clinic setting. In the U.S., the non-surgical procedure is performed in the retinal specialist's office. ILUVIEN, which is non-bioerodable, provides consistent delivery as a result of its constant surface area. This provides a sustained therapeutic effect on DME, and an adverse event profile that is predictable and manageable by a retinal physician. The Company relies on its manufacturers to purchase materials from third-party suppliers necessary to produce ILUVIEN. The Company competes with pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. The Company's competitors include Roche, Allergan, Regeneron and Bayer. The Company owns six U.S. utility patents, one U.S. design patent and two U.S. patent applications as well as numerous foreign counterparts to many of these patents and patent applications relating to ILUVIEN or the ILUVIEN applicator. The Company licensed two European patents from pSivida directed to its low-dose device and have an application pending directed to its applicator system for ILUVIEN. The manufacture and packaging of pharmaceutical products such as ILUVIEN and any future product candidates are regulated by the FDA and similar foreign regulatory agencies.

Ratios

vs
industry
vs
history
P/S 2.44
ALIM's P/S is ranked higher than
51% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. ALIM: 2.44 )
Ranked among companies with meaningful P/S only.
ALIM' s P/S Range Over the Past 10 Years
Min: 2.38  Med: 25.88 Max: 853.33
Current: 2.44
2.38
853.33
Current Ratio 0.88
ALIM's Current Ratio is ranked lower than
91% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ALIM: 0.88 )
Ranked among companies with meaningful Current Ratio only.
ALIM' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.17 Max: 11.78
Current: 0.88
0.59
11.78
Quick Ratio 0.85
ALIM's Quick Ratio is ranked lower than
83% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. ALIM: 0.85 )
Ranked among companies with meaningful Quick Ratio only.
ALIM' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.04 Max: 11.78
Current: 0.85
0.59
11.78
Days Inventory 326.95
ALIM's Days Inventory is ranked lower than
93% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. ALIM: 326.95 )
Ranked among companies with meaningful Days Inventory only.
ALIM' s Days Inventory Range Over the Past 10 Years
Min: 245.39  Med: 340.35 Max: 445.49
Current: 326.95
245.39
445.49
Days Sales Outstanding 136.35
ALIM's Days Sales Outstanding is ranked lower than
83% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. ALIM: 136.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALIM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.83  Med: 97.49 Max: 159.4
Current: 136.35
36.83
159.4
Days Payable 765.38
ALIM's Days Payable is ranked higher than
99% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. ALIM: 765.38 )
Ranked among companies with meaningful Days Payable only.
ALIM' s Days Payable Range Over the Past 10 Years
Min: 339.92  Med: 829.02 Max: 1270.92
Current: 765.38
339.92
1270.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.09
ALIM's Price/Median PS Value is ranked higher than
99% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. ALIM: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
ALIM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.03 Max: 30.5
Current: 0.09
0.12
30.5
Earnings Yield (Greenblatt) (%) -26.38
ALIM's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ALIM: -26.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALIM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -29.34  Med: 0.00 Max: 0
Current: -26.38
-29.34
0

More Statistics

Revenue (TTM) (Mil) $24.30
EPS (TTM) $ -0.71
Beta1.45
Short Percentage of Float8.21%
52-Week Range $1.26 - 5.15
Shares Outstanding (Mil)45.10

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.40
EPS w/o NRI ($) -0.40
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ALIM

Headlines

Articles On GuruFocus.com
Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 

More From Other Websites
ALIMERA SCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2016
Alimera Sciences to Present at the LD Micro Invitational Conference Jun 02 2016
Alimera Sciences to Present at the LD Micro Invitational Conference Jun 02 2016
ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 27 2016
Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision... May 23 2016
Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision... May 23 2016
ETF’s with exposure to Alimera Sciences, Inc. : May 19, 2016 May 19 2016
Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
ALIMERA SCIENCES INC Financials May 17 2016
Alimera Sciences to Present at the UBS Global Healthcare Conference May 17 2016
Alimera Sciences to Present at the UBS Global Healthcare Conference May 17 2016
Alimera Sciences' ILUVIEN® Data Presented at SFO 2016 May 11 2016
Edited Transcript of ALIM earnings conference call or presentation 5-May-16 2:00pm GMT May 06 2016
ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report May 06 2016
Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO May 06 2016
Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO May 06 2016
ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition May 05 2016
Alimera Sciences reports 1Q loss May 04 2016
Alimera Sciences reports 1Q loss May 04 2016
Alimera Sciences Announces First Quarter 2016 Financial Results May 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)